FLT3 (F594_R595insREY)

FLT3 · Variant type: indel · HGVS: p.F594_R595insREY

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Sunitinib	99.2%	0.8%	91.73
2	Gilteritinib	98.7%	1.3%	88.97
3	Brigatinib	98.6%	1.4%	82.96
4	Fostamatinib	98.5%	1.5%	96.74
5	Ponatinib	98.2%	1.8%	78.23
6	Pacritinib	98.0%	2.0%	88.64
7	Quizartinib	96.8%	3.2%	99.50
8	Pralsetinib	96.4%	3.6%	93.43
9	Selpercatinib	96.3%	3.7%	96.72
10	Defactinib	95.2%	4.8%	92.68
11	Entrectinib	95.0%	5.0%	93.69
12	Nintedanib	94.3%	5.7%	90.23
13	Fedratinib	94.0%	6.0%	96.21
14	Avapritinib	91.8%	8.2%	97.73
15	Sorafenib	91.7%	8.3%	96.72
16	Alectinib	90.5%	9.5%	95.49
17	Canertinib	82.0%	18.0%	96.49
18	Cabozantinib	79.5%	20.5%	92.73
19	Rabusertib	77.9%	22.1%	98.74
20	Erlotinib	77.2%	22.8%	99.75
21	Vandetanib	71.5%	28.5%	95.74
22	Osimertinib	68.9%	31.1%	97.24
23	Pazopanib	64.7%	35.3%	97.49
24	Alpelisib	61.8%	38.2%	97.22
25	Tivozanib	60.8%	39.2%	92.42

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Sunitinib	99.2%	98.7%	+0.5%
Gilteritinib	98.7%	99.2%	-0.5%
Brigatinib	98.6%	98.1%	+0.5%
Fostamatinib	98.5%	97.2%	+1.3%
Ponatinib	98.2%	97.9%	+0.3%
Pacritinib	98.0%	93.6%	+4.5%
Quizartinib	96.8%	97.9%	-1.1%
Pralsetinib	96.4%	97.6%	-1.2%
Selpercatinib	96.3%	96.1%	+0.2%
Defactinib	95.2%	94.6%	+0.6%
Entrectinib	95.0%	96.1%	-1.1%
Nintedanib	94.3%	95.2%	-1.0%
Fedratinib	94.0%	98.2%	-4.2%
Avapritinib	91.8%	88.6%	+3.2%
Sorafenib	91.7%	97.3%	-5.6%
Alectinib	90.5%	84.5%	+6.0%
Canertinib	82.0%	86.3%	-4.3%
Cabozantinib	79.5%	95.0%	-15.5%
Rabusertib	77.9%	—	—
Erlotinib	77.2%	—	—
Vandetanib	71.5%	—	—
Osimertinib	68.9%	—	—
Pazopanib	64.7%	—	—
Alpelisib	61.8%	—	—
Tivozanib	60.8%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 15.1ms